Second-line FOLFOX chemotherapy for advanced biliary tract cancer
- PMID: 34197750
- DOI: 10.1016/S1470-2045(21)00280-1
Second-line FOLFOX chemotherapy for advanced biliary tract cancer
Conflict of interest statement
We declare no competing interests.
Comment in
-
Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.Lancet Oncol. 2021 Jul;22(7):e288-e289. doi: 10.1016/S1470-2045(21)00341-7. Lancet Oncol. 2021. PMID: 34197751 No abstract available.
Comment on
-
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30. Lancet Oncol. 2021. PMID: 33798493 Free PMC article. Clinical Trial.
-
Second-line FOLFOX chemotherapy for advanced biliary tract cancer.Lancet Oncol. 2021 Jul;22(7):e284. doi: 10.1016/S1470-2045(21)00211-4. Lancet Oncol. 2021. PMID: 34197747 No abstract available.
-
Second-line FOLFOX chemotherapy for advanced biliary tract cancer.Lancet Oncol. 2021 Jul;22(7):e285. doi: 10.1016/S1470-2045(21)00243-6. Lancet Oncol. 2021. PMID: 34197748 No abstract available.
-
Second-line FOLFOX chemotherapy for advanced biliary tract cancer.Lancet Oncol. 2021 Jul;22(7):e286. doi: 10.1016/S1470-2045(21)00269-2. Lancet Oncol. 2021. PMID: 34197749 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical